- Home
- BUJA vs AFMD Comparison
BUJA vs AFMD Comparison
Compare BUJA & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- AFMD
- Stock Information
- Founded
- BUJA 2022
- AFMD 2000
- Country
- BUJA Malaysia
- AFMD Germany
- Employees
- BUJA N/A
- AFMD N/A
- Industry
- BUJA Blank Checks
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- AFMD Health Care
- Exchange
- BUJA Nasdaq
- AFMD Nasdaq
- Market Cap
- BUJA N/A
- AFMD 53.3M
- IPO Year
- BUJA 2023
- AFMD 2014
- Fundamental
- Price
- BUJA $10.96
- AFMD $3.36
- Analyst Decision
- BUJA
- AFMD Strong Buy
- Analyst Count
- BUJA 0
- AFMD 5
- Target Price
- BUJA N/A
- AFMD $16.25
- AVG Volume (30 Days)
- BUJA 2.7K
- AFMD 80.0K
- Earning Date
- BUJA 01-01-0001
- AFMD 11-12-2024
- Dividend Yield
- BUJA N/A
- AFMD N/A
- EPS Growth
- BUJA N/A
- AFMD N/A
- EPS
- BUJA 0.29
- AFMD N/A
- Revenue
- BUJA N/A
- AFMD $7,959,927.00
- Revenue This Year
- BUJA N/A
- AFMD N/A
- Revenue Next Year
- BUJA N/A
- AFMD $48.98
- P/E Ratio
- BUJA $37.13
- AFMD N/A
- Revenue Growth
- BUJA N/A
- AFMD N/A
- 52 Week Low
- BUJA $10.30
- AFMD $2.92
- 52 Week High
- BUJA $12.18
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- AFMD 44.84
- Support Level
- BUJA $10.85
- AFMD $3.28
- Resistance Level
- BUJA $10.85
- AFMD $3.51
- Average True Range (ATR)
- BUJA 0.00
- AFMD 0.17
- MACD
- BUJA -0.00
- AFMD 0.04
- Stochastic Oscillator
- BUJA 87.50
- AFMD 55.79
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.